



OPEN ACCESS

Edited and reviewed by:

Théophile Godfraind,
Université catholique de Louvain,
Belgium

***Correspondence:**

Frontiers Editorial Office
editorial.office@frontiersin.org

Specialty section:

This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology

Received: 14 July 2016

Accepted: 14 July 2016

Published: 21 July 2016

Citation:

Frontiers Editorial Office (2016)
Expression of Concern: Discoidin
Domain Receptors: Potential Actors
and Targets in Cancer.
Front. Pharmacol. 7:228.
doi: 10.3389/fphar.2016.00228

Expression of Concern: Discoidin Domain Receptors: Potential Actors and Targets in Cancer

Frontiers Editorial Office *

An expression of concern on

Discoidin Domain Receptors: Potential Actors and Targets in Cancer

by Rammal, H., Saby, C., Magnien, K., Van-Gulick, L., Garnotel, R., Buache, E., et al. (2016). *Front. Pharmacol.* 7:55. doi: 10.3389/fphar.2016.00055

With this notice, Frontiers states its awareness of concerns regarding a number of instances of failure to adequately cite or attribute credit appropriately within the above-referenced article. Prof. Théophile Godfraind and Prof. Olivier Feron, Chief Editors of the journal and specialty section respectively, will direct an investigation in full accordance with our procedures. The situation will be updated as soon as the investigation is complete.

Copyright © 2016 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.